source
- Mark Cuban's Cost Plus Drugs targets rare disease market with custom n-of-1 therapiesMark Cuban's Cost Plus Drugs, known for low-cost generics, is expanding into rare disease treatments. The company has dedicated part of its new manufacturing plant to producing custom "n-of-1" the…
- Lilly advances retatrutide toward sleep-apnea marketEli Lilly is moving its triple-agonist drug retatrutide closer to a potential launch for sleep-apnea. The company, which expects to introduce the drug for obesity next year, is now gathering data i…